An, Won Suk; Lee, Su Mi; Son, Young Ki; Kim, Seong Eun; Kim, Ki Hyun; Han, Jin Yeong; Bae, Hae Rahn; Rha, Seo Hee; Park, Yongsoon
Nutrition research (New York, N.Y.)
2012Jul ; 32 ( 7 ) :495-502.
PMID : 22901557
ÀúÀÚ »ó¼¼Á¤º¸
An, Won Suk -
Lee, Su Mi -
Son, Young Ki -
Kim, Seong Eun -
Kim, Ki Hyun -
Han, Jin Yeong -
Bae, Hae Rahn -
Rha, Seo Hee -
Park, Yongsoon -
ABSTRACT
Vitamin D deficiency, low levels of fetuin-A, and fibroblast growth factor 23 (FGF-23) are related to vascular calcification, which is associated with cardiovascular disease. We hypothesized that omega-3 fatty acid (FA), which has cardioprotective properties, modifies vitamin D status, fetuin-A, and FGF-23 levels in dialysis patients. In a randomized, open-label, controlled study, a total of 47 patients treated with dialysis for at least 1 year were randomized to treatment for 6 months with omega-3 FAs (Omacor, 3 g/d; Pronova, Sandefjord, Norway) or a control group. Levels of fetuin-A and FGF-23 were measured by enzyme-linked immunoassay, 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D were measured by radioimmunoassay. The mean age of the enrolled patients was 57.4 +/- 10.4 years, and mean dialysis duration was 46.5 +/- 28.1 months. Twenty-seven hemodialysis patients and 16 peritoneal dialysis patients finished this trial. After 6 months, the levels of 1,25-dihydroxyvitamin D and fetuin-A were significantly increased in the group taking the omega-3 FA supplement compared with baseline. Levels of calcium, phosphorous, parathyroid hormone, 25-hydroxyvitamin D, FGF-23, and lipid profiles were not significantly changed in the omega-3 FA-supplemented group after 6 months compared with baseline. The erythrocyte membrane contents of eicosapentaenoic acid and docosahexaenoic acid were significantly increased, and oleic acid content was significantly decreased in the omega-3 FA-supplemented group after 6 months compared with baseline. Regarding vascular calcification and cardiovascular disease, omega-3 FA supplementation may have a clinical benefit caused by activating vitamin D, increasing fetuin-A levels, and modifying erythrocyte membrane FA contents in dialysis patients. CI - Copyright (c) 2012 Elsevier Inc. All rights reserved.
1,25-dihydroxyvitamin D Dialysis Fetuin-A Fibroblast growth factor 23 Omega-3 fatty acid Human
MESH
Adult, Aged, Aged, 80 and over, Calcium/blood, Cardiovascular Diseases/drug therapy/physiopathology, Diet, *Dietary Supplements, Docosahexaenoic Acids/administration & dosage, Drug Combinations, Eicosapentaenoic Acid/administration & dosage, Energy Intake, Erythrocyte Membrane/drug effects/metabolism, Fatty Acids, Omega-3/*administration & dosage/blood, Female, Humans, Male, Middle Aged, Oleic Acid/blood, Parathyroid Hormone/blood, Peritoneal Dialysis, Phosphorus/blood, Radioimmunoassay, *Renal Dialysis, Vascular Calcification/drug therapy/physiopathology, Vitamin D/administration & dosage/*analogs & derivatives/blood, alpha-2-HS-Glycoprotein/*analysis
¸µÅ©